Innate Pharma to Participate in the Kempen Life Sciences Conference

Key Takeaways

• Executives attend Kempen Life Sciences conference in Amsterdam
• Conference dates: April 15‑16, 2026
• Innate Pharma showcases ADC IPH4502 and antibodies Lacutamab, Monalizumab
• Partnerships include AstraZeneca, Sanofi for immuno‑oncology development
• Company listed on Euronext Paris and Nasdaq

Summary

Innate Pharma announced that senior executives will hold one‑on‑one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15‑16, 2026. The biotech firm will use the event to showcase its pipeline, including the Nectin‑4 ADC IPH4502, the anti‑KIR3DL2 antibody Lacutamab, and the AstraZeneca‑partnered anti‑NKG2A antibody Monalizumab. Innate highlighted its collaborations with AstraZeneca and Sanofi and reiterated its dual listing on Euronext Paris and Nasdaq. The press release underscores the company’s focus on expanding investor engagement ahead of key clinical milestones.

Pulse Analysis

The Kempen Life Sciences Conference, held in Amsterdam on April 15‑16, 2026, gathers leading biotech firms, investors, and analysts to discuss emerging therapeutic platforms. By scheduling one‑on‑one meetings, Innate Pharma’s senior leadership signals a proactive stance toward capital markets, aiming to deepen relationships with existing shareholders and attract new institutional interest. Such direct dialogue is especially valuable for clinical‑stage companies, where pipeline milestones often drive valuation swings. The conference’s European setting also underscores Innate’s dual‑listing strategy, leveraging both Euronext Paris and Nasdaq to broaden its investor base.

Innate’s portfolio, highlighted at the event, includes the Nectin‑4 antibody‑drug conjugate IPH4502, the anti‑KIR3DL2 candidate Lacutamab, and the AstraZeneca‑co‑developed anti‑NKG2A antibody Monalizumab. Each asset targets high‑unmet‑need oncology indications, from solid tumours to peripheral T‑cell lymphomas and non‑small cell lung cancer. The company’s collaborations with AstraZeneca and Sanofi provide not only validation of its antibody‑engineering expertise but also access to larger development resources and commercial pathways. Investors will be keen to gauge progress on upcoming trial readouts and regulatory filings.

The visibility gained at Kempen could translate into stronger market positioning as the immuno‑oncology sector attracts heightened capital inflows. With the biotech funding environment stabilizing after a volatile 2023‑24 period, firms that demonstrate clear pipeline differentiation and robust partnership networks are better positioned for premium valuations. Innate’s strategic outreach may also set the stage for future licensing or co‑development deals, especially if early data from IPH4502 or Lacutamab prove compelling. Overall, the conference offers a timely platform for the company to reinforce its growth narrative and secure the financial backing needed to advance its late‑stage candidates.